Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

Inclusion Criteria:

* Stage M1a, M1b, M1c biopsy proven metastatic melanoma
* Failure of at least one prior chemotherapy regimen of DTIC and/or temozolomide with/without interleukin-2 (IL-2).
* Karnofsky performance status greater than/equal to 80%.
* Measurable metastatic lesions by physical exam or scans.
* Acceptable CBC and blood chemistry results
* Adequate renal function.
* Written informed consent.

Exclusion Criteria:

* Patients who have received more than 8 cycles of chemotherapy for metastatic melanoma.
* Patients who have received chemotherapy less than 4 weeks before beginning the trial.
* Patients who have received interferon (IFN) alpha-2b or granulocyte-monocyte colony-stimulating factor (GM-CSF) less than 4 weeks before beginning the trial.
* Patients who have received high-dose IL-2 less than 4 weeks before beginning the trial.
* Patients with a history of central nervous system (CNS) metastatic melanoma.
* More than 5 hepatic lesions or any hepatic lesion larger than 5 cm.
* Baseline serum LDH greater than 4 times the upper limit of normal.
* Patients who are HIV positive.
* Patients who are pregnant.
* Patients who have received corticosteroids or other agents less than 4 weeks before beginning the trial.
* Patients with asthma, angina pectoris or congestive heart failure.
* Patients with autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.
* Patients with active infections including viral hepatitis.
* Patients with a history of any other neoplastic disease less than 5 years ago (carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin, however, can be admitted to the study).